HOME
>
臨床医学：内科
>
循環器一般
> DATA UPDATE 循環系

DATA UPDATE 循環系

出版社：	先端医学社
著者：	山口徹(編集) 日和田邦男(編集) 齋藤康(編集)
発行日：	1998-08-25
分野：	臨床医学：内科 > 循環器一般
ISBN：	9784915892615
電子書籍版：	1998-08-25 （第1版第1刷）

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

本書を企画するにあたって、比較的専門書などにでてくる頻度の高い、しかも科学的根拠にもとづく医療をおこなううえで重要な大規模臨床試験を中心に選び出し、それに解説をしていただくという方法をとった。(序文より)

目次

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

心臓

P.23 掲載の参考文献

1) Singh, S. N., Fletcher, R. D., Fisher, S. G. et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N. Engl. J. Med. 333:77-82, 1995

2) Hammill, S. C. and Packer, D. L.: Amiodarone in congestive heart failure: unravelling the GESICA and CHF-STAT differences. Heart 75:6-7, 1996

P.27 掲載の参考文献

1) The CONSENSUS Trial Study Group.: Effects of enalapril on mortality in severe heart failure. N. Engl J. Med. 316:1429-1435, 1987

2) Lubsen, J. for CONSENSUS Ethical Review Committee Appendix: Monitoring methods, considerations, and statement of the CONSENSUS ethical review committee. Am. J. Cardiol. 62:73A-74A, 1986

3) Swedberg, K. and Kjekshus, J.: Effect of enalapril on mortality in congestive heart failure, Follow-up survival data from the CONSENSUS Trial. Drugs 39 (suppl. 4): S 49-S 52, 1990

4) Eriksson, S. V., Offstad, J. and Kjekshus, J.: M-mode echocardiography in patients with severe congestive heart failure, a subgroup analysis in the CONSENSUS. Drugs 39 (suppl. 4): S 43-S 48, 1990

5) Swedberg, K., Eneroth, P., Kjekshus, J. et al.: Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (Follow-up of the CONSENSUS Trial). Am. J. Cardiol. 66:40D-45D, 1990

6) Swedberg, K., Eneroth, P., Kjekshus, J. et al.: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82:1730-1736, 1990

7) Ljungman, S., Kjekshus, J., Swedberg, K. et al.: Renal function in severe congestive heart failure during treatment with enalapril survival study (CONSENSUS) Trial. Am. J. Cardiol. 70:479-487, 1992

8) Broqvist, M., Dahlstoem, U., Karlsson, E. et al.: Muscle water and electrolytes in severe chronic congestive heart failure before and after treatment with enalapril. Heart J. 13:243-250, 1992

P.29 掲載の参考文献

1) Swedberg, K., Held, P., Kjekshus, J. et al.: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction, Results of the Cooperative New Scandinavian Enalapril Sruvival Study II (CONSENsus II). N. Engl. J. Med. 327:678-684, 1992

2) Carsternsen, S., Bonarjee, V. V. S., Berning, J. et al.: Effects of early enalapril treatment on global and regional wall motion in acute myocardial infarction. Am. Heart J. 129:1101-1108, 1995

3) Bonarjee, V. V. S., Carstensen, S., Caidahl, K. et al.: Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril theray. Am, J. Cardil. 72:1004-1009, 1993

4) Dickstein, K. and Aarsland, T. for the Nordic Enalapril Exercise Trial.: Effect on exercise performance of enalapril therapy initiated early after myocardial infarction. J. Am. Coll. Cardiol. 22:975-983, 1993

5) Sigurdsson, A. and Swedberg, K.: Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur. Heart J. 15 (suppl.B): 14-19, 1994

6) Bonarjee, V. V. S., Omland, T., Nilsen, D. W. T. et al.: Left ventricular volumes, ejection fraction, and plasmaproatrial natriuretic factor (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. Br. Heart J. 73:506-510, 1995

P.32 掲載の参考文献

1) The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336:525-533, 1997

2) The Digitalis Investigation Group: Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control. Clin. Trials. 17:77-97, 1996

P.35 掲載の参考文献

1) Doval, H. C., Nul, D. R., Grancelli, H. O. et al.: Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 344:493-498, 1994

2) Nul, D. R., Doval, H. C., Grancelli, H. O. et al.: Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J. Am. Coll. Cardiol. 29: 1199-1205, 1997

P.37 掲載の参考文献

1) Waagstein, F., Bristow, M. R., Swedberg, K. et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446, 1993

P.39 掲載の参考文献

1) Bristow, M. R., Gilbert, E. M., Abraham, K. et al.: For the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807-2816, 1996

P.41 掲載の参考文献

1) Packer, M., O'Connor, C. M., Ghali, J. K. et al.: For the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N. Engl. J. Med. 335:1107-1114, 1996

P.42 掲載の参考文献

1) Packer, M., Colucci, W. S., Sackner-Bernstein, J. D. et al.: For the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 94:2793-2799, 1996

P.45 掲載の参考文献

1) Packer, M., Carver, J. R., Rodeheffer, R. J. et al.: Effect of oral milrinone of mortality in severe chronic heart failure. N. Engl. J. Med. 325:1468-1475, 1991

P.47 掲載の参考文献

1) Packer, M., Gheorghiade, M., Young, J. B. et al.: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N. Engl. J. Med. 329:1-7, 1993

P.49 掲載の参考文献

1) The SOLVD investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:293-302, 1991

2) The SOLVD investigators: Effect of enalaprila on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327:685-691, 1992

3) Francis, G. S., Benedict, C., Johnstone, D. E. et al.: Comparison of neuroendocrine activation in patients with and without congestive heart failure A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 82:1724-1729, 1990

4) Konstum, M. A., Rousseau, M. F., Kronenberg, M. W. et al.: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 86:431-438, 1992

5) Kostis, J. B.: The Effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am. J. Hyper tens. 8:909-914, 1995

6) Kostis, J. B., Shelton, B., Gosselin, G. et al.: Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD). Am. Heart. J. 131:350-355, 1996

7) Torre-Amione, G., Kapadia, S., Benedict, C. et al.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection faraction: a report from the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardil. 27:1201-1206, 1996

P.51 掲載の参考文献

1) Packer, M., Bristow, M. R., Cohn, J. N. et al.: For the US Carvedilol Heart Failure Study Group. Effect of carvedilol on morbidity and mortality in chronic heart failure. N. Engl.J. Med. 334:1349-1355, 1996

P.53 掲載の参考文献

1) Cohn, J. N., Archibald, D. G., Ziesche, M. P. S. et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure, Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314:1547-1552, 1986

2) Cohn, J. N.: The vasodilator-heart failure trials (V-HEFT) Mechanistic data from the VA cooperative studies. Circulation 87:VI1-VI4. 1993

3) Carson, P., Johnson, G., Fletcher, R. et al.: Mild systolic dysfunction in heart failure (left ventricular ejection fraction>35%): Baseline characteristics, prognosis and response to therapy in the vasodilator in heart failure trials (V-HeFT) J. Am. Coll. Cardiol. 27:642-649, 1996

4) Boden, W. E., Ziesche, S., Carson, P. E. et al.: Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. Am. J. Cardiol. 77:1078-1082. 1996

P.55 掲載の参考文献

1) Cohn, J. N., Johnson, G., Ziesche, M. P. S. et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325:303-310, 1991

2) Cohn, J. N.: The vasodilator-heart failure trials (V-HeFT) Mechanistic data from the VA cooperative studies. Circulation 87(6):VI1-VI14. 1993

3) Cohn, J. N., Johnson, G. R., Shabetai, R. et al.: Ejection fraction, peakaexercise oxygen consumption, cardiothracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinats of prognosis in heart failure. Circulation 87 (suppl. 6):S15-S16, 1993

4) Goldman, S., Johnson, G., Cohn, J. N. et al.: Mechanism of death in heart failure The vasodilator-heart failure trials. Circutation 87 (suppl. 6): S24-S31, 1993

5) Francis, G. S., Cohn, J. N., Johnson, G. et al.: Plasma norepinephrine, plasma renin activity, and congestive heart failure Retations to survival and the effects of therapy in V-HeFT II. Circutation 87 (suppl. 6):S40-S48, 1993

6) Dunkman, W. B., Johnson, G., Carson, P. E. et al.: Incidence of thromboembolic events in congestive heart failure. Circutation 87 (suppl. 6): S94-S101, 1993

7) Carson, P. E., Johnson, G. R., Dunkman, W. B. et al.: The influence of atrial fibrillation on prognosis in mild to moderate heart failure The V-HeFT Studies. Circutation 87 (suppl. 6): S102- S11O, 1993

P.57 掲載の参考文献

1) Boden, W. E., Ziesche, S., Carson, P. E. et al.: Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. Am. J. Cardiol. 77:1078-1082, 1996

2) Cohn, J. N.: Treatment of moderate heart failure: V-HeFT III. AHA 1995

3) Cohn, J. N., on behalf of the V-HeFT investigators et al.: Sequential neurohormonal response to felodipine in enalapril-treated heart failure: V-HeFT III. ACC 1995

P.59 掲載の参考文献

1) The Xamoterol in Severe Heart failure Study Group. Xamoterol in severe heart failure. Lancet 336:1-6, 1990

P.61 掲載の参考文献

1) Peterson, P., Boysen, G., Godtfredsen, J. et al.: Placebo controlled, randomized trial of warfarin and aspirin for prevention of thrombembolic complication in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1:175-179, 1989

2) The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N. Engl. J. Med. 323:1505-1511, 1990

3) Ezekowitz, M. D., Bridgers, S. L, James, K. E. et al.: Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N. Engl. J. Med. 327:1406-1412, 1992

4) Connolly, S. J., Laupacic, A., Gent, M. et al: Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J. Am. Coll. Cardiol. 18:349-355, 1991

P.63 掲載の参考文献

1) Burkart, F., Pfisterer, M., Kiowski, W. et al.: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhytmic study of infarct survival. J. Am. Coll. Cardiol. 16:1711-1718, 1990

P.65 掲載の参考文献

1) The Cardiac Arrhythmia Pilot Study (CAPS) investigators: Effects of encainide, flecainide, imipramine and morcizine on ventricular arrhythmia during the year after acute myocardial infarction: The CAPS. Am. J. Cardiol. 61:501-509, 1988

P.67 掲載の参考文献

1) The CASCADE Investigators: Cardiac arrest n Seattle: conventional versus amiodarone drog evaluation (the CASCADE study). Am. J. Car diol. 67:578-584, 1991

2) The CASCADE Investigators: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am. J. Cardiol. 72:280-287, 1993

P.69 掲載の参考文献

1) Siebels, J., Cappato, R., Ruppel, R. et al.: The CASH Investigators. Preliminary Results of the Cardiac Arrest Study Hamburg (CASH). Am. J. Cardiol. 72:109F-113F, 1993

P.71 掲載の参考文献

1) Debras, Echt., Philip, R. Liebson., Brent, Mitchell. et al. and CAST investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324:781, 1991

2) The Cardiac Arrhythmia Suppression Trial II Investigators: Effects of the antiarrhythmic agent morcizine on survival after myocardial infarction. N. Engl. J. Med. 327:227, 1992

P.73 掲載の参考文献

1) The ESVEM Investigators: Determinants of predicted efficacy of antiarrhythmic drugs in the electrophysiologic study versus electrocardiographic monitoring trial. Circulation 87:323-329, 1993

2) Allan, M. Greenspan. Determinants of antiarrhythmic drug efficacy for ventricular tachyarrhythmias using ambulatory monitoring and electrophsiological techniques. Circulation 87:643-645, 1993

3) Mason, J. W. for the ESVEM Investigators: A comparison of electrophisiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N. Engl. J. Med. 329:452-458, 1993

4) Mason, J. W.: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N. Engl. J. Med. 329:452-458, 1993

P.75 掲載の参考文献

1) Wilber, D. J., Olshansky, B., Moran, J. F. et al.: Electrophysiological testing and nonsustained ventricular tachycardia: use and limitation in patients with coronary artery disease and impaired ventricular function. Circulation 82:350-358, 1990

2) Moss, A. J., Hall, J., Cannom, D. S. et al.: For the MADIT Investigators: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N. Engl. J. Med. 335:1933-1940, 1996

P.77 掲載の参考文献

1) Stroke Prevention in Atrial Fibrillation Investigators: Stroke Prevention in Atrial Fibrillation study: final results. Circulation 84:527-539, 1991

2) Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 343:687-691, 1994

3) Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomaized clinical trial. Lancet 348:633-638, 1996

P.79 掲載の参考文献

1) Ezekowitz, M. D., Bridgers, S. L., James, K. E. et al.: Warfarin in teh prevention of stroke associated with non-rheumatic atrial fibrillation. N. Engl. J. Med. 327:1406-1412, 1992

P.81 掲載の参考文献

1) Waldo, A. L., Camm, A. J., de Ruyter, H. et al: Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: Rotioale, design, and methods (the AWORD trial). Am. J. Cardiol. 75:1023-1027, 1995

2) Waldo, A. L., Camm, A. J., de Ruyter, H. et al.: For the SWORD investigators: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348:7-12, 1996

P.83 掲載の参考文献

1) The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828, 1993

2) Pfeffer, M. A., Braunwald, E, Moye, L. A. et al.: Effect of captoril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: result of the survival and ventricular enlargement trial. N. Eng. J. Med. 327:669-677, 1992

P.85 掲載の参考文献

1) Verstraete, M., Bernard, R., Borry, M. et al.: Randomized trial of intravenous recombinant tissue-plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet i: 842-847, 1985

2) Verstraete, M., Bleifeld, W., Brower, R. W. et al.: Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet ii: 965-969, 1985

3) Verstraete, M., Arnold, A., Brower, R. W. et al.: Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. Am. J. Cardiol. 60:231-237, 1987

4) Simoons, M. L., Arnold, A. E. R., Betriu, A. et al.: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet i: 197-203, 1988

5) Werf, F. and Arnold, A. E. R., for the European Cooperative Study Group for recombinant tissue type plasminogen activator. Br. Med. J. 297:1374-1379, 1988

6) Bono, D. P., Simoons, M. L, Tijssen, J. et al.: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br. Heart J. 67:122-128, 1992

7) Simoons, M. L., Arnout, J., Brand, M. et al.: Retreatment with alteplase for the early signs of reocclusion after thrombolysis. Am. J. Cardiol. 71:524-528, 1993

P.87 掲載の参考文献

1) GISSI: Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet ii: 871-874, 1987

2) GISSI-2: GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336:65-71, 1990

3) GISSI-3: GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115-1122, 1994

P.88 掲載の参考文献

1) The GUSTO investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329:673-682, 1993

P.93 掲載の参考文献

1) ISIS-1 collaborative group: Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet ii:57-66, 1986

2) ISIS-2 collaborative group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet ii: 349-3360, 1988

3) ISIS-3 (Third International Study of Infarct Suryival) collaborative group: ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339:753-770, 1992

4) ISIS-4 collaborative group: ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345:669-685, 1995

P.95 掲載の参考文献

1) LATE study group.: Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 342:759-766, 1993

2) ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. Lancet ii:349-360, 1988

P.97 掲載の参考文献

1) Grines, C. L., Browne, K. F., Marco, J. et al.: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med. 328:673-679, 1993

2) Stone, G. W., Grines, C. L., Browne, K. F. et al.: Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the primary angioplasty in myocardial infarction (PAMI) trial. J. Am. Coll. Cardiol. 25:370-377, 1995

P.99 掲載の参考文献

1) The GUSTO Investigators.: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329:673-682, 1993

2) Ellis, S. G., da Silva, E. R., Heyndrickx, G. et al.: Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 90:2280-2284, 1994

P.101 掲載の参考文献

1) Pfeffer, M. A., Braunwald, E., Moye, L. A. et al.: Effect of captoril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: result of the survival and ventricuar enlargement trial. N. Eng. J. Med. 327:669-677, 1992

2) Lamas, G. A., Flaker, G. C., Mitchell, G. et al.: Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation 92: 1101-1109, 1995

P.104 掲載の参考文献

1) Topol, E. J., Califf, R. M., George, B. S. et al.: A randmized trial of immediate versus elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N. Engl. J. Med. 317:581-588, 1987

2) Topol, E. J., Califf, R. M., George, B. S. et al.: Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 77:1101-1107, 1988

3) Topol, E. J., George, B. S., Kereiakes, D. J. et al.: A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 79:281-286, 1989

4) Topol, E. J., Ellis S. G., Califf, R. M. et al.: Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J. Am. Coll. Cardiol. 14:877-884, 1989

5) Califf, R. M., Topol, E. J., Stack, R. S. et al.: Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction-phase 5 randomized trial. Circulation 83:1543-1556, 1991

6) Topol, E. J., Califf, R. M., Vandormael, M. et al.: A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 85:2090-2099, 1992

7) Wall, T. C., Califf, R. M., George, B. S. et al.: Accelerated plasminogen activator dose regimens for coronary thrombolysis. J. Am. Coll. Cardiol. 19:482-489, 1992

8) Kleiman, N. S., Ohman, E. M., Califf, R. M. et al.: Profound inhibition of platelete aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J. Am. Coll. Cardiol. 22:381-389, 1993

9) Wall, T. C., Califf, R. M., Blankenship, J. et al.: Intravenous Fluosol in the treatment of acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction 9 trial. Circulation 90:114-120, 1994

P.107 掲載の参考文献

1) Anderson, J. L., Rothbard, R. L., Hackworthy, R. A. et al.: Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J. Am. Coll. Cardiol. 11:1153-1163, 1988

2) Anderson, J. L., Becker, L. C., Sorensen, S. G. et al.: Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity 1-day coronary artery patency. J. Am. Coll. Cardiol. 20:753-766, 1992

P.113 掲載の参考文献

1) Chesebro, J., Knatterud, G., Roberts, R. et al.: Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: climical findings through hospital discharge. Circulation 76:142-154, 1987

2) Terrin, M., Williams, D., Kleiman, N. et al.: Two-and three-year results of the thrombolysis in myocardial infarction (TIMI) phase II clinical trial. J. Am. Coll. Cardiol. 22:1763-1772, 1993

3) The TIMI IIIA Investigators: Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: results of the thrombolysis in myocardial isohemia (TIMI IIIA) trial. Circulation 87:38-52, 1993

4) The TIMI IIIB Investigators: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 89:1545-1556, 1994

5) Cannon, C., McCabe, C., Diver, D. et al.: Comparison of front-loaded recombinant tissue-type plasminogen activator, Anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J. Am., Coll. Cardiol. 24:1602-1610, 1994

6) Cannon, C., McCabe, C., Henry, T. et al.: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J. Am. Coll. Cardiol. 23:993-1003, 1994

7) Lee, L. for the TIMI 6 Investigators: Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 6 trial. Am. J. Cardiol. 75:7-13, 1995

8) Fuchs, J., Cannon, C. and the TIMI 7 Investigators: Hirulog in the treatment of unstable angina: results of the thrombin inhibition in myocardial ischemia (TIMI) 7 trial. Circulation 92:727-733, 1995

9) Antman, E. for the TIMI 9A Investigators: Hirudin in acute myocardial infarction: safety report from the thrombolysis and thombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90:1624-1630, 1994

10) Antman, E. for the TIMI 9B Investigators: Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 94:911-921, 1996

11) Cannon, C., McCabe, C., Gibson, M. et al.: TNK-Tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial. Circulation 95:351-356, 1997

P.115 掲載の参考文献

1) Boissel, J-P., Leizorovicz, A., Picolet, H. et al.: Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am, J. Cardiol. 66:251-260, 1990

P.117 掲載の参考文献

1) Peto, R., Gray, R., Collins, R. et al.: Randomized trial of prophylactic daily aspirin in British male doctors. Br. Med. J. 296:313-316

2) Hennekens, C. H., Buring, J. E., Sandercock, P. et al.: Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80:749-756, 1989

P.119 掲載の参考文献

1) BHAT Research Group: A randomized trial of propranolol in patients with acute myocardial infarction: I. mortality results. JAMA 247: 1707-1714, 1982

2) BHAT Research Group: A randomized trial of propranolol in patients with acute myocardial infarction: I. morbidity results. JAMA 250: 2814-2819, 1983

P.121 掲載の参考文献

1) The Danish study group on verapamil in myocardial infarction: verapamil in acute myocardial infarction. Eur. Heart J. 5:516-528, 1984

P.123 掲載の参考文献

1) The Danish study group on verapamil in myocardial infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish verapamil infarction trial II-DAVITII). Am, J. Cardiol. 66:779-785, 1990

P.125 掲載の参考文献

1) The MDPIT Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N. Engl. J. Med. 319:385-392, 1988

P.127 掲載の参考文献

1) The Persantine-Aspirin Reinfarction Study Research Group: Persantine and aspirin in coronary heart disease. Circulatrion 62:449-461, 1980

2) Klimt, C. R., Knatterud, G. L., Stamler, J. et al.: for the Investigator Group: Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J. Am. Coll. Cardiol. 7:251-269, 1986

P.129 掲載の参考文献

1) Steering Committee of the Physicians' Health Study Research Group: Final report of the aspirin component of the ongoing Physician's Health Study. N. Engl. J. Med. 321:129-135, 1989

P.131 掲載の参考文献

1) Juul-Moller, S., Edvardsson, N., Jahnmatz, B. et al.: Double-blind trial of aspirin in primary prevention of myocardial infarcrion in patients with stable chronic angina pectoris. Lancet 340:1421-1425, 1992

P.133 掲載の参考文献

1) The Israeli SPRINT Study Group: Secondary prevention Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur. Heart J. 9:354-364, 1988

2) Goldbourt, U., Behar, S., Reicher-Reiss, H. et al: Early administration of nifedipine in suspected acute myocardial infarction. Arch. Intern. Med. 153:345-353, 1993

P.135 掲載の参考文献

1) Smith, P., Arnesen, H. and Holme, I.: The effect of warfarin on mortality and reinfarction after myocardial infarction. N. Engl. J. Med. 323:147-152, 1990

P.137 掲載の参考文献

1) Serruys, P. W., de Jaegere, P., Kiemeneij, F. et al.: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331:489-495, 1994

2) Fishman, D. L., Leon, M. B., Bain, D. S. et al.: A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331:496-501, 1994

3) Ozaki, Y., Keane, D., Serruys, P. W. et al.: Six-month clinical and angiographic outcome of the new less shortening wallstent in native coronary arteries. Circulation 93:2114-2120, 1996

P.139 掲載の参考文献

1) Topol, E. J., Leya, F., Pinkerton, C. A. etal.: A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N. Engl. J. Med. 329:221-227, 1993

2) Elliott, J. M., Berdan, L. G., Holmes, D. R. et al.: One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). Circulation 91:2158-2166, 1995

3) Baim, D. S., Cutlip, D. E., Sharma, S. K. et al.: Final results of the Balloon vs Optimal Atherectomy Trial(BOAT). Circulation 97: 322-331, 1998

P.141 掲載の参考文献

1) Theroux, P., Kouz, S., Roy, L. et al.: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 94:899-905, 1996

P.143 掲載の参考文献

1) Piek, J., Schroder, E., Gurne, O. et al.: Dopper endpoints balloon angioplasty trial Europe (final results of the debate trial): Eur. Heart J. 17 (suppl.): 86, 1996

2) Serruys, P. W. and di Mario, C.: Prognostic value of coronary flow velocity and diameter stenosis in assessing the short and long term outcome of baloon angioplasty: The DEBATE study (Dopper Endpoints Balloon Angioplasty Trial Europe). Circulation 94 (suppl. 8): 1-317, 1996

3) Sunamura, M., di Mario, C., Piek, J. et al.: Cyclic flow variations after angioplasty: A rare phenomenon predictive of immediate complications. Am. Heart J. 131:843-848, 1996

P.145 掲載の参考文献

1) Topol, E. J., Califf, R. M., Weisman, H. F. et al.: Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343:881-886, 1994

2) The EPIC Investigators: Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330:956-961, 1994

P.149 掲載の参考文献

1) Hermans, W. R., Rensing, B. J., Foley, D. P. et al.: Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. The Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstraction and Restenosis (MERCATOR) Study Group. J. Cardiovasc, Pharmacol. 22 (suppl. 4):S45-S57, 1993

2) Faxon, D. P. on behalf of the Multicenter American Reserch trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstraction and Restenosis (MARCATOR) Study Group.: Effect of High Dose Angiotensin-Converting Enzyme Inhibition on Restenosis: Final Results of the MARCATOR Study, a Multicenter, Double-Blind, Placebo-Controlled Trial of Cilazapril. J. Am. Coll. Cardiol. 25:362-369, 1995

P.151 掲載の参考文献

1) Baim, D. S., Kent, K. M., King III, S. B. et al.: Evaluating New Devices Acute (ln-Hospital) Results From the New Approaches to Coronary Interventional Registry. Circulation 89:471-481, 1994

2) Steenkiste, A. R., Baim, D. S., Sipperly, M. E. et al.: The NACI Registry: An Instrument for the Evaluation of New Approaches to Coronary Intervention. Cathe. Cardiovasc. Diagn. 23:270-281, 1991

3) Detre, K. M., Baim, D., Buchbinder, M. et al.: Baseline Characteristics and Therapeutic Goals in the New Approaches to Coronary Intervention (NHCI) Registry. Coron. Artery Dis. 4:1013-1022, 1993

P.153 掲載の参考文献

1) Detre, K., Holubkov, R., Kelsey, S. et al.: Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood institute Registy. N. Engl. J. Med. 318:265-270, 1988

2) Detre, K. M., Myler, R. K., Kelsey, S. F. et al.: Baseline characteristics of patients in the National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. Am. J. Cardiol. 54:7C-11C, 1984

P.155 掲載の参考文献

1) Fishman, D. L., Leon, M. B., Bain, D. S. et al.: A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331:496-501, 1994

2) Serruys, P. W., de Jaegere, P., Kiemeneij, F. et al.: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331:489-495, 1994

3) Ozaki, Y., Keane, D., Serruys, P. W. et al.: Six-month clinical and angiographic outcome of the new less shortening wallstent in native coronary arteries. Circulation 93:2114-2120, 1996

4) Ozaki, Y., Violaris, and Serruys, P. W.: New stent technologies. Prog. Cardiovasc. Dis. 39: 129-140, 1996

P.157 掲載の参考文献

1) Penn, I. M., Ricci, D. R., Almond, D. G. et al.: Coronary artery stenting reduces restenosis: final results from the trial of angioplasty and stents in canada (TASC-1) Circulation I-279 (abstract), 1995

2) Penn, I. M., Ricci, D. R., Almond, D. G. et al.: Stenting results increased early complications and fewer late reinterventions: final clinical data from the trial of angioplasty and stents in canada (TASC-1) Circulation I-475(abstract), 1995

3) Chauhan, A., Penn, I., Donald, R. R. et al.: Trial angioplasty and stents in canada (TASC-1): is stent mania justified? A sobering insight from TASC-1. Circulation I-324(abstract), 1996

4) Schomig, A., Neumann, F. J., Kastrati, A. et al.: a Randomized comparison of antiplatelet and anticoagulation therapy after coronary stent placement. N. Engl. J. Med. 334:1084-1089, 1996

P.159 掲載の参考文献

1) The TREAT Study investigators. The Impact of Tranilast on Restenosis Following Coronary Angioplasty: the Tranilast Restenosis Following Angioplasty Trial (TREAT). Circulation 90:I-652, 1994

2) Tamai, H., Katou, K., Hayakawa, H. et al.: TREAT-2 study investigators. The Impact of Tranilast on Restenosis Following Coronary Angioplasty: the second Tranilast Restenosis Following Angioplasty Trial (TREAT-2 Study). Circulation 94:I-620, 1996

P.161 掲載の参考文献

1) Tzivoni, D., Gavish, A., Zin, D. et al.: Prognostic significance of ischemic episodes in patients with previous myocardial infarction. Am. J. Cardiol. 62:661-664, 1988

2) Weiner, D. A., Ryan, T. J., Parsons, L. et al.: Prevalence and prognostic significance of silent and symptomatic ischemia after coronary bypass surgery: a report from the Coronary Artery Surgery Study (CASS) randomized population J. Am. Coll. Cardiol. 18:343-348, 1991

3) Pepine, C. J., Cohn, P. F., Deedwania, P. C. et al.: Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ishemia Study (ASIST). Circulation 90:762-768, 1994

P.163 掲載の参考文献

1) BARI, CABRI, EAST, GABI, and RITA: coronary angioplasty on trial. Lancet 335:1315-1316, 1990

2) Detre, K. M., Holmes, D. R., Holubkov, R. et al.: Incidence of consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 82:739-750, 1990

P.165 掲載の参考文献

1) Stone, P. H., Gibson, R. S., Glasser, S. P. et al.: Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation 82:1962-1972, 1990

2) Andrews, T. C., Fenton, T., Toyosaki, N. et al.: Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. Circulation 88:92-100, 1993

3) Borzak, S., Fenton, T., Glasser, S. P. et al.: Discordance between effects of anti-ischemic therapy on ambulatory ischemia, exercise performance and angina pectoris. J. Am. Coll. Cardiol. 21:1605-1611, 1993

P.167 掲載の参考文献

1) Deanfield, J. E., Shea, M., Ribiero, P. et al.: Transient ST-segment depression as a marker of myocardial ischemia during daily life. Am. J. Cardiol. 54:1195-1200, 1984

2) Raby, K. E., Barry, J., Vita, G. et al.: Prognostic significance of asymptomatic ischemia's response to medical therapy. Circulation 88 (suppl. I): I-298 (Abstract) 1993

3) Hill, J. A., Gonzalez, J. I., Kolb, R. et al.: Effects of atenolol alone, nifedipine alone and their combination on ambulant myocardial ischemia. Am. J. Cardiol. 67:671-675, 1991

P.169 掲載の参考文献

1) The Bypass Angioplasty Revascularization Investigation (BARI) Investigators.: Comparison of coronary bypass surgery and angiopasty in patients with multivessel disease. N. Engl. J. Med. 335:217-225, 1996

2) The BARI Investigators.: Protocol for the bypass angioplasty revascularization investigation. Circulation 84:V 1-V 27, 1991

P.171 掲載の参考文献

1) CABRI Trial Participants: First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation). Lancet 346:1179-1184, 1995

2) Editorial. BARI, CABRI, EAST, GABI, and RITA: Coronary angioplasty on trial. Lancet 335:1315-1316, 1990

3) Rodriguez, A., Boullon, F., Perez, B. N. et al.: Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel coronary disease (ERACI). J. Am. Coll. Cardiol. 22:1060-1067, 1993

P.173 掲載の参考文献

1) Alderman, E. L, Bourassa, M. G., Cohen, L. S. et al.: Ten-year follow-up of survival and myocardial infarction in the randomized coronary artery surgery study. Circulation 82:1629-1646, 1990

2) CASS Principal Investigators and their associates: Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery bypass surgery B. Survival data. Circulation 68:939-950, 1983

3) The National Heart, Lung and Blood Institute: Coronary Artery Surgery Study (CASS). Circulation 63 (suppl. I): I-I-I-81, 1981

P.175 掲載の参考文献

1) King, S. B. III., Lembo, N. J., Weintraub, W. S. et al.: For the Emory Angioplasty versus Surgery Trial (EAST). a randomized trial comparing coronary angioplasty with coronary bypass surgery. N. Engl. J. Med. 331:1044-1050, 1994

2) King, S. B. III., Lembo, N. J., Weintraub, W. S. et al.: Emory Angioplasty versus Surgery Trial (EAST): Design, recruitment, and baseline description of patients. Am. J. Cardiol. 75:42c-59c, 1995

3) Zhao, X. Q., Brown, B. G., Stewart, D. K. et al.: Effectiveness of revascularization in the Emory angioplasty versus surgery trial: a randomized comparison of coronary angioplasty with coronary bypass surgery. Circulation 93:1954-1962, 1996

P.177 掲載の参考文献

1) Varnauskas, E., European Coronary Surgery Study Group: Twelve-year follow-up of survival in the randomized European coronary surgery study. N. Engl. J. Med. 319:332-337, 1988

2) Varnauskas, E., European Coronary Surgery Study Group: Survival, myocardial infarction, and employment status in a prospective randomized study of coronary bypass surgery. Circulation 72(suppl. V):V-90, 1985

3) European Coronary Surgery Study Group: Long-term results of prospective randomized study of coronary artery bypass surgery in stable angina pectoris. Lancet 2:1173-1180, 1982

P.179 掲載の参考文献

1) Hamm, C. W., Reimers, J., Ischinger, T. et al.: A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease for GABI: the German Angioplasty Bypass sugery Investigation trial. N. Engl. J. Med. 331:1037-1043, 1994

P.182 掲載の参考文献

1) RITA Trial Participants: Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 341:573-580, 1993

2) Sculpher, M., Seed, P., Henderson, R. A. et al.: Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial Lancet 344:927-930, 1994

3) Pocock, S. J., Henderson, R. A., Seed, P. et al.: Qulity of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery: 3-year follow-up in the Randomized Intervention Treatment of Anginal (RITA) trial. Circulation 94:135-142, 1996

P.185 掲載の参考文献

1) Von, Arnim, T., for the TIBBS investigators: Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J. Am. Coll. Cardiol. 25:231-238, 1995

2) Parmly, W. W., Nestro, R. W., Singh, B. N. et al.: Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. N-CAP Study Group. J. Am. Coll. Cardiol. 19:1380-1389, 1992

3) de Vries, R. J., van den Heuvel, A. F., Lok, D. J. et al.: Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN). Int. J. Cardiol. 57:143-150, 1996

P.187 掲載の参考文献

1) The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group: Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N. Engl. J. Med. 311:1333-1339, 1984

2) Peduzzi, P. P. and Hultgren, H. N.: Effect of medical vs surgical treatment on symptoms in stable angina pectoris. The Veterans Administration Cooperative Study of Surgery for coronary Arterial Occlusive Disease. Circulation 60:888-900, 1979

3) Detre, K., Hultgren, H., Takaro, T.: Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. III Methods baseline characteristics, including experience with medical treatment. Am. J. Cardiol. 40:212-225, 1977

P.189 掲載の参考文献

1) Levy, D., Larson, M. G., Vasan, R. S. et al.: The progression from hypertension to congestive heart failure. JAMA 275:1557-1562, 1996

P.191 掲載の参考文献

1) Dannenberg, A. L., Keller, J. B., Wilson, P. W. F. et al.: Leisure time physical activity in the Framingham Offispring Study. Am. J. Epidemiol. 129:76-88, 1989

2) Folsom, A. R., Caspersen, C. J., Taylor, H. L. et al.: Leisure time physical activity and its relationship to coronary risk factors in a population-based sample. Am. J. Epidemiol. 121:570-579, 1985

3) Leon, A. S., Connet, J., Jacobs, D. R. etal: Leisure-time physical activity levels and risk of coronary heart disease and death: the Multiple Risk Factor Intervention Trial. JAMA 258:2388-2395, 1987

4) Sallis, J. F., Haskell, W. L., Wood, P. D. et al.: Physical activity assessment methodology in the Five-City Project. Am. J. Epidemiol. 121:91-106, 1985

P.193 掲載の参考文献

1) American College of Sports Medicine: Guideline for Exercise Testing and Prescription. 4th ed., Lea & Febiger, Philadelphia, 1991

2) Williams, R. S., McKinnis, R. A., Cobb, F. R. et al.: Effects of physical conditioning on left ventricular ejection fraction in patients with coronary artery disease. Circulation 70:69-75, 1984

3) Froelicher, V., Jensen, D., Genter, D., et al.: Randomized trial of exercise training in patients with coronary heart dise ase. JAMA 252:1291-1297, 1984

4) Jensen, D., Atwood, J., Froelicher, V. et al: Improvement of ventricular function during exercise studied with radionuclide ventriculography following cardiac rehabilitation. Am. J. Cardiol. 46:770-777, 1980

高血圧

P.197 掲載の参考文献

1) Maschio, G., Alberti, D., Janin, G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. 344:939-945, 1996

2) United States Renal Data System. Excerpts from the United States Renal Date System. 1994 Annual data report: Executive summary. Am. J. Kidney Dis. 24(suppll. 2): S12-S17, 1994

3) Zucchelli, P. and Zuccala, A.: Recent data on hypertension and progressive renal disease. J. Hum. Hypertens. 10:679-682, 1996

P.199 掲載の参考文献

1) Staessen, J. A., Bieniaszewski, L., Buntinx, F. et al.: The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. Hypertension 26:942-949, 1995

2) 今井潤: 血圧日内変動からみた高血圧治療のあり方, 高血圧治療と管理の手引き2:1-25, 1997

P.201 掲載の参考文献

1) Hansson, L.: The BBB Study: The effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in "well-treated" hypertensive Patients. Blood Press. 3:248-254, 1994

2) Mancia, G., Sega, R., Milesi, C. et al.: Blood-pressure control in the hypertensive population. Lancet 349:454-457, 1997

3) Imai, Y., Tsuji, I., Nagai, K. et al.: Ambulatory blood pressure monitoring in evaluating the prevalence of hypertension in adults in Ohasama, a rural Japanese Community. Hypertens. Res. 19:207-212, 1996

P.203 掲載の参考文献

1) Barer, D. H., Cruickshank, J. M., Ebrahim, S. B. et al.: Low dose β blockade in acute stroke ("BEST" trial): an evaluation. Br. Med. J. 296:737-741, 1988

P.205 掲載の参考文献

1) Bulpitt, C. J., Palmar, A. J., Fletcher, A. E. et al.: Optimal blood pressure control in treated hypertensive patients. Report from the Department of Health Hypertension Care Computing Project(DHCCP). Circulation 90:225-233, 1994

2) Bulpitt, C. J., Beevers, D. G., Butler, A. et al.: The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP). J. Hypertens. 4:93-99, 1986

3) Fletcher, A., Beevers, D. G., Bulpitt, C. et al.: Beta adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: a report from the DHSS Hypertension Care Computing Project (DHCCP). J. Human Hypertens. 2:219-227, 1988

4) Palmar, A. J., Beevers, D. G., Bulpitt, C. J. et al.: Mortality associated with captopril and enalapril: a report from the DHSS Hypertension Care Computing Project. J. Hypertens. 8:521-524, 1990

P.207 掲載の参考文献

1) Amery, A., Birkenhager, W., Brixko, P. et al,: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet i: 1349-1354, 1985

2) Amery, A., Birkenhager, W., Brixko, P. et al.: Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60. Lancet ii: 589-592, 1986

P.209 掲載の参考文献

1) Luomanmaki, K., Inkovaara, J., Hartikainen, M. et al.: Efficacy and tolerability of isradipine and metoprolol in treatment of hypertension: the Finnish Isradipine Study in Hypertension (FISH). J. Cardiovasc. Pharmacol. 20:296-303, 1992

P.211 掲載の参考文献

1) 尾前照雄, 松岡博昭, 荒川規矩男ほか: 軽・中等症高血圧症におけるACE阻害薬とCa拮抗薬の比較試験-GLANT研究から-日本医事新報 3630:26-34, 1993

2) The GLANT Study Group: A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension-The GLANT Study-.Hypertens. Res. 18:235-244, 1995

P.213 掲載の参考文献

1) Coope, J. and Warrender, T. S.: Randomized trial of treatment of hypertension in the elderly patients in primary care. Br. Med. J. 293:1145-1151, 1986

P.215 掲載の参考文献

1) The HOT study group: The hypertension optimal treatment study (the HOT study). Blood Press. 2:62-68, 1993

2) Hansson, L., Zanchetti, A. for the HOT study group: The hypertension optimal treatment (HOT) study-patient characteristics: randomization, risk profiles, and early blood pessure results. Blood Press. 3:322-327, 1994

3) Hansson, L., Zanchetti, A., Carruthers, S. G. et al.: Effects of inteusive blood-pressure lowering and acetylsalicylic acid in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998

P.217 掲載の参考文献

1) Lievre, M., Gueret, P., Gayet, C. et al.: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 25:92-97, 1995

2) Casale, P. N., Devereux, R. B., Milner, M. et al.: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann. Intern. Med. 105:173-178, 1986

3) Levy, D., Garrison, R. J., Davage, D. D. et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322:1561-1566, 1990

4) Schmieder, R. E., Martus, P., Kingbeil, A.: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275:1507-1513, 1996

5) Linz, W., Schaper, J., Wiemer, G. et al: Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br. J. Pharmacol. 107:970-975, 1992

P.219 掲載の参考文献

1) Wikstrand, J., Warnold, I., Olsson, G. et al.: Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259:1976-1982, 1988

2) Wikstrand, J., Warnold, I., Tuomilehto, J. et al.: Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 17:579-588, 1991

3) Olsson, G., Tuomilehto, J., Berglund, G. et al.: Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am. J. Hypertens. 4:151-158, 1991

P.221 掲載の参考文献

1) Krakoff, L. R., Bravo, E. L., Tuck, M. L. et al.: Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. Am. J. Hypertens. 3:318S-325S, 1990

2) Bravo, E. L., Krakoff, L. R., Tuck, M. L. et al.: Antihypertensive effectiveness of nifedipine gastrointestinal therapeutic system in the elderly Am. J. Hypertens. 3:326S-325S, 1990

P.223 掲載の参考文献

1) Borhani, N. O., Mercuri, M., Borhani, P. A. et al.: Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA 276:785-791, 1996

2) Furberg, C. D., Byington, R. P., Borhani, N. O. et al.: Designfeatures: Multicenter Isradipine Diuretic Atherosclerosis study (MIDAS). Am. J. Med. 86 (suppl. 4A): 37-39, 1989

P.225 掲載の参考文献

1) MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304:405-412, 1992

2) Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. BMJ 291:97-104, 1985

P.227 掲載の参考文献

1) Stumpe, K. O. and Overlack, A.: A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Am. J. Cardiol. 71:32E-37E, 1993

2) Overlack, A., Adamczak, M., Bachmann, W. et al.: ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. Am. J. Med. 97:126-134, 1994

P.229 掲載の参考文献

1) Rich, M. W., LaPalio, L, Schork, A., and The SAFE Coordinators.: The safety after fifty evaluation trial: Evaluation of the safety and efficacy of antihypertensive therapy with metoprolol inpatie 50 to 75 years of age: Study design. Am. Heart J. 116:301-304, 1988

2) LaPalio, L., Schork, A., Glasser, S. et al: Safety and efficancy of metoprolol in the treatment of hypertension in the elderly. J. Am. Geriatr. Soc. 40:354-358, 1992

P.231 掲載の参考文献

1) SHEP Cooperative Research Group.: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 265:3255-3264, 1991

2) Black, H. R., Curb, J. D., Pressel, L. et al.: Systolic hypertension in the elderly program (SHEP). Hypertension 17 (suppl. 2):II-1-II-171, 1991

P.233 掲載の参考文献

1) Libretti, A. and Catalano, M.: Lipid profile during antihypertensive treatment. The SLIP study. Drugs 46 (suppl. 2):16-23, 1993

P.235 掲載の参考文献

1) Gong, L., Zhang, W., Zhu, Y. et al.: Shanghai trial of nifedipine in the elderly (STONE). J. Hypertens. 14:1237-1245, 1996

P.237 掲載の参考文献

1) Hansson, L., Dahlof, B., Ekbom, T. et al.: Key learning from the STOP-Hypertension study: An update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly. Cardiovasc. Drug Ther. 4:1253-1256, 1990

2) Dahlof, B., Lindholm, L. H., Hansson, L. et al.: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338:1281-1285, 1991

P.239 掲載の参考文献

1) Hansson, S. J. L., Schersten, B., Kullman, S. et al.: Swedish Isradipine Study in Hypertension: Evaluation of quality of life, safety and efficacy. J. Cardiovasc, Pharmacol. 18 (suppl. 3): S7-S8, 1991

2) 築山久一郎, 大塚啓子:β遮断薬とQOL. 血圧 2:324-329, 1995

P.241 掲載の参考文献

1) Staessen, J. A., Fagard, R., Thijs, L. et al.: Randomized doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757-764, 1997

P.243 掲載の参考文献

1) Wassertheil-Smoller, S. Oberman, A., Blaufox, M. D. et al.: The Trial of Antihyertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am. J. Hypertens. 5:37-44, 1992

2) Kaplan, N. M.: Commentary on the Trial of Antihypertensive Interventions and Management (TAIM) Study. Am. J. Hypertens. 5:47-48, 1992

3) Davis, B. R., Oberman, A., Blaufox, M. D. et al.: Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons withmild hypertension. Am. J. Hypertens. 7:926-932, 1994

P.245 掲載の参考文献

1) Neaton, J. D., Grimm, R. H., Prineas, R. J. et al.: Treatment of mild hypertension: Final results. JAMA 270:713-724, 1993

2) Liebson, P. R., Grandits, G. A., Dianzumba, S. et al.: Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 91:698-706, 1995

3) Beil, A. H. and Schmieder, R. E.: Salt intake as a determinant of cardiac hypertrophy. Blood Press. 4 (suppl. 2): 30-34, 1995

P.247 掲載の参考文献

1) Davis, B. R., Cutler, J. A., Gordon, D. J. et al.: Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am. J. Hypertens. 9:342-360, 1996

P.248 掲載の参考文献

1) The CAPPP group: The captopril prevention project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J. Hypertens. 8:985-990, 1990

2) Hansson, L.: The captopril prevention project (CAPPP):description and status. Am J. Hypertens. 7:S82-S83, 1994

P.249 掲載の参考文献

1) 蔵本築: 老年者高血圧長期治療試験 (NICS-EH) 中間検討成績. Prog. Med. 14:927-943, 1994

P.250 掲載の参考文献

1) The NORDIL group: The Nordic diltiazem study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Press. 2:312-321, 1993

P.251 掲載の参考文献

1) Neal, B. and MacMahon, S.: PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee. J. Hypertens. 13:1869-1873, 1995

2) Whitlock, G., MacMahon, S., Anderson, C. et al.: Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. Clin. Exp. Hvpertens. 19:843-855, 1997

P.252 掲載の参考文献

1) Stumpe, K. O., Ludwig, M, Heagerty, A. M. et al.: Vascular wall thickness in hypertension: the Perindopril Regresssion of Vascular Thickening European Community trial: PROTECT. Am. J. Cardiol. 76:50E-54E, 1995

P.253 掲載の参考文献

1) Dahlof, B., Hansson, L., Lindholm, L. H. et al.: STOP-Hyperension-2: a prospective intervention trial of"newer"versus"older"treatment alternative in old patients with hypertension. Blood Press. 2:136-141, 1993

2) Lindholm, L. H., Hansson, L., Dahlof, B. et al.: The swedish trial in old patients with hypertension-2 (STOP-Hypertension-2): a progress report. Blood Press. 5:300-304, 1996

P.254 掲載の参考文献

1) Zanchetti, A., Magnani, B. and Dal Palu, C.: Atherosclerosis and calcium antagonists: The VHAS. J. Hum. Hypertens. 6(suppl. 2): S 45-S 48, 1992

2) Henry, P. D.: Calcium antagonists as anti-atherosclerotic agents. Arteriosclerosis 10:963-965, 1990

脂質

P.257 掲載の参考文献

1) Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994

2) Pyorala, K., Pedersen, T. R., Kjekshus, J. et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997

3) Scandinavian Simvastatin Survival Study Group: Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345:1274-1275, 1995

P.259 掲載の参考文献

1) Ericsson, C. G., Hamsten, A., Nilsson, J. et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853, 1996

2) Jukema, J. F., Bruschke, A. V. G., van Boven, A. J. et al. on behalf of the REGRESS Study Group.: Effect of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540, 1995

3) MAAS investigators.: Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet 344:633-638, 1994

P.261 掲載の参考文献

1) Bierenbaum, M. L., Fleischman, A. I., Raichelson, R. I. et al.: Ten-year experience of modified-fat diets in youger men with coronary heart-disease.: Lancet i:1404-1407, 1973

2) Bierenbaum, M. L., Fleischman, A. I., Green, D. P. et al.: The 5-year experience of modified fat diets on younger men with coronary heart disease.: Circulation 42:943-952, 1970

P.263 掲載の参考文献

1) Frank, M., Sack, M. D., Marc, A. et al.: The Effect Of Pravastatin On Coronary Events After Myocardial Infarction In Patients With Average Cholesterol Levels. N. Engl. J. Med. 335:1001-1010, 1996

2) Scandinavian Simvastatin Survival Group.: Baseline Serum Cholesterol and Treatment Effect In The Scandinavian Simvastatin Survival Study (4S). Lancet 345:1274-1275, 1995

P.265 掲載の参考文献

1) The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231:360-381, 1975

2) Canner, P. L, Berge, K. G., Wenger, N. K. et al.: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J. Am. Coll. Cardiol. 8:1245-1255, 1986

P.267 掲載の参考文献

1) Cashin-Hemphill, L, Mark, W. J., Pogoda, J. M. et al.: Beneficial effects of colestipolniacin on coronary atherosclerosis. A four-year follow up. JAMA 264:3013-3017, 1990

2) Blankenhorn, D. H., Nessim, A. N., Johnson, R. L. et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary bypass grafts. JAMA 257:3233-3240, 1987

P.269 掲載の参考文献

1) Dorr, A. E., Gundersen, K., Schneider, J. C. Jr. et al.: Colestipol hydrochloride in hypercholesterolemic patients-effect on serum cholesterol and mortality. J. Chronic. Dis. 31:5-14, 1978

2) Ast, M. and Frishman, W. H.:Bile acid sequestrants. J. Clin. Pharmacol. 30:99-106, 1990

P.271 掲載の参考文献

1) Brown, G., Albers, J. J., Fisher L. D. et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323:1289-1298, 1990

P.273 掲載の参考文献

1) Frick, M. H., Elo. O., Haapa, K. et al.: Helsinki Heart Syudy: Primary prevention trial with gemfibrizil in middle-aged men with dyslipidemia. N. Engl. L. Med. 317:1237-1245, 1987

2) Manninen, V., Elo, M. O., Frick, M. H. et al.: Lipid Alterations and Decline in the incidence of Coronary Heart Disease in the Helsinki Heart Study 260:641-651, 1988

3) Lipid Research Clinics Program The Lipid Reseach Ckinics Coronary Primary Prevention Trial results. 1. Reduction in incidence of coronary heart disease. JAMA 251:351-364, 1984

4) Heinonen, O. P., Huttunen, J. K., Manninen, V. et al: The Helsinki Heart Study: Coronary heart disease incidence during an extended follow-up. J. lntern. Med. 235:41-49, 1994

P.275 掲載の参考文献

1) Nikkila, E. A., Viikinkoski, P., Valle, M. et al.: Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. Br. Med. J. 289:220-223, 1984

2) Frick, M. H., Valle M. and Harjola, P. T.: Progression of coronary artery disease in randomized medical and surgical patients over a 5-year angiographic follow-up. Am. J. Cardiol. 52:681-685, 1983

3) Bruschke, A. V. G., Wijers, T. S., Kolsters, W. et al.: The anatomic evolution of coronary artery disease demonstrated by coronary arteriography in 256 nonoperated patients. Circulation 63:527-536, 1981

P.277 掲載の参考文献

1) Ornish, D., Brown, S. E., Scherwitz, L. W. et al.: Can Lifestyle Changes Reverse Coronary Heart Disease? The Lifestyle Heart Trial. Lancet 336:129-133, 1990

P.279 掲載の参考文献

1) The LRC Program.: LRC-CPPT results: I. reduction in incidence of coronary heart disease. JAMA 251:351-364, 1984

2) The LRC Program: The lipid research clinics coronary primary prevention trial results:II. the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984

3) The Lipid Research Clinics Investigators. LRC-CPPT: results of 6 years of post-trial follow-up. Arch. Intern. Med. 152:1399-1410, 1992

4) Morris, D. L., Kritchevsky, S. B. and Davis, C. E.: Serum carotenoids and coronary heart disease: LRC-CPPT and follow-up study. JAMA 272:1439-1441, 1994

P.281 掲載の参考文献

1) Dayton, S., Pearce, M. L., Hashimoto, S. et al.: A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 39 and 40 (suppl. 2):1-63, 1969

P.283 掲載の参考文献

1) MAAS investigators: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344: 633-638, 1994

P.285 掲載の参考文献

1) Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., et al.: Coronary angiographic changes with lovastatin theraphy: the monitored atherosclerosis regression study (MARS). Ann. Intern. Med. 199:969-976, 1993

2) Blankenhorn, D. H., Nessim, S. A., Johnson, R. L. et al.: Beneficial effects of combined colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257:3233-3240, 1987

3) Buchwald, H., Varco, R. L, Matts, JP. et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N. Engl. J. Med. 323:946-955, 1990

P.287 掲載の参考文献

1) Multiple Risk Factor Intrvetion Trial Reseach Group.: Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings ralated to a priori hypotheses of the trial. JAMA 263:1795-1801, 1990

2) Holme, I., Hjermann, I., Hegleland, A. et al.: The Oslo Study: diet and antismoking advice: additional results from 5-year primary preventive trial in middle-aged men. Prev. Med. 14:279-292, 1985

3) World Health Organization European Collaborative Group.: European Collborative Trial of Multifactorial Prevention of Coronary Heart Disease: final report on the 6-year results. Lancet i: 869-872, 1986

P.289 掲載の参考文献

1) Anderssen, S. A., Hjermann, I., Urdal, P. et al.: Improved carbohydrate metabolism after physical traqining and dietary intervention in individuals with the atherothrombogenic syndrome. Oslo diet and Exercise Study. A randamized trials. J. Intern. Med. 240:203-209, 1996

2) Hjermann, I., Holme, I. and Leren, P.: Oslo study diet and antismoking trial. Am. J. Med. 80: (suppl. 2A) 7-12, 1986

3) Hjerman, I.: Strategies for dietary and antismoking advice practical experiances from the Oslo study. Drugs 36:(suppl. 3) 105-109, 1988

4) Anderssen, S. A., Holme, I., Urdal, P. et al.: Diet and exercise intervention have favourable effects on blood pressure in mild hypertensives: the Oslo Diet and Exercise Study (ODES). Blood Press. 4:343-349, 1995

P.291 掲載の参考文献

1) Haheim, L. L., Holme, I., Hjermann, I. et al.: The predictability of risk factors with respect to incidence and mortality of myocardial infarction and total mortality. A 12-year follow-up of the Oslo Study, Norway. J. Intern. Med. 234:17-24, 1993

2) Holme, I., Helgeland, A., Hjermann, I. et al.: Four and two-thirds years incidence of coronary heart disease in middle-aged men: The Oslo Study. Am. J. Epidemiol. 112:149-160, 1980

3) Hjermann, I., Byre, K. V., Holme, I. et al.: Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet ii:1303-1310, 1981

P.294 掲載の参考文献

1) Pitt, B., Ellis, SG., Mancini, G. B. J. et al.: Design and recruitment in the United States of a multicenter quantitative angiographic trial of Pravastatin to Limit Atherosclerosis in the Coronary Arteries (PLAC-I), Am. J. Cardiol. 72:31-35, 1993

2) Mancini, G. B. J., Simon, S. B., McGillem, M. J. et al.: Automated quantitative coronary arterioraphy: morphologic and physiologic validationin vivo of a rapid digital angiographic method. Circultation 75:452-560, 1987

3) Nutrition Committee, American Heart Association: Dietary guidelines for healthy American adults. A statement for physicians and health professionals by the Nutrition Committee, American Heart Association, Circulation 74:1465A-1468A, 1986

4) Pitt, B., Mancini, G. B. J., Ellis, S. G., Rosman, H. S., et al.: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events, J. Am. Coll. Cardiol. 26:1133-1139, 1995

P.297 掲載の参考文献

1) Junkema, J. W., Bruschke, A. V. G., Boven, A. J. et al.: Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The regression growth evaluation statin study (REGRESS). Circulation 91:2528-2540, 1995

2) Pitt, B. Mancini, G. B., Ellis, S. G. et al.: Pravastatin limitation of atherosclerosis in the coronary arteries (PLACI): reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 26:1133-1139, 1995

P.299 掲載の参考文献

1) Kane, J. P., Malloy, M. J., Ports, T. A. et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007-3012, 1990

2) Brown, G., Albers, J. J., Fisher, L. D. et al.: Regression of coronary artery disease as a result of interim lipid-lowering therapy in men with high levels of apoprotein B. N. Engl. J. Med. 323:1289-1298, 1990

P.301 掲載の参考文献

1) Report by a Research Committee of the Scottish Society of Physicians Ischemic heart disease: A secondary prevention trial using clofibrate. Br. Med. J. 4:775-784, 1971

2) Dewar, H. A. and Oliver, MF.: Secondary prevention trials using clofibrate: A joint commentary on the Newcastle and Scottish trials. Br. Med. J. 4:784-786, 1971

P.303 掲載の参考文献

1) Arntzenius, A. C., Kromhout, D., Barth, J. D. et al.: Diet, lipoproteins, and the progression of coronary atherosclerosis. N. Engl. J. Med. 312:805-811, 1985

2) Ornish, D., Brown, S. E., Scherwitz, L. W. et al.: Can lifestyle changes reverse coronary heart disease? Lancet 336:129-133, 1990

3) Roussouw, J. E., Lewis, B. and Rifkind, B. M.: The value of lowering cholesterol after myocardial infarction. N. Engl. J. Med. 323:1112-1119, 1990

P.305 掲載の参考文献

1) Ringler, S. H.: Primary prevention of coronary heart disease by diet. Bull, N. Y. Acad. Med. 44:936-949, 1968

P.307 掲載の参考文献

1) Arntzenius, C. A., Kromhout, D., Barth, J. D. et al.: Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden intervention trial. N. Engl. J. Med. 312:805-11, 1985

2) Keys, A., Anderson, J. T. and Grande, F.: Serum cholesterol response to changes in the diet. IV. Particular saturated fatty acids in the diet. Metabolism 14:776-787, 1965

3) Blankenhorn, D. H., Brooks, S. H., Selzer, R. H. et al.: The rate of atherosclerosis change during treatment of hyperlipoproteinemia. Circulation 57:355-361, 1978

P.309 掲載の参考文献

1) Woodhill, J. M., Palmer, A. J., Leelarthaepin, B. et al.: Low fat, low cholesterol diet in secondary prevention of coronary heart disease, Adv. Exp. Med. Biol. 109:317--330, 1978

P.311 掲載の参考文献

1) Krasno, L. R. and Kidera, G. J.: Clofibrate in coronary heart disease Effect on morbidity and mortarity. JAMA 219:845-851, 1972

2) Carson, P. L, McDonald, S., Prichard, T. et al.: Effect of Atromid on platelet stickiness. J. Atheroscler Res. 3:619-622, 1963

P.313 掲載の参考文献

1) Shepherd, J., Cobbe, S. M., Ford, I. et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1301-1307, 1995

2) The West of Scotland Coronary Prevention Study Group: A coronary primary prevention study of Scottish men aged 45-64 years: trial design. J. Clin. Epidemiol. 45:849-860, 1992

3) Jones, H. P.: Trials of lipid-lowering therapy in primary prevention of coronary heary disease. Curr. Opin. Lipidol. 6:365-368, 1995

その他

P.316 掲載の参考文献

1) The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338:1345-1349, 1991

P.318 掲載の参考文献

1) Diener, H. C., Cunha, L., Forbes, C. et al.: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143:1-3, 1996

2) ESPS Group: European Stroke Prevention Study. Stroke 21:1122-1130, 1990

3) Muller, T. H., Su, C. A. P. F., Weisenberger, H. et al.: Dipyridamole alone or combined with low-dose acetyl-salicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br. J. Clin. Pharmacol. 30:179-186, 1990

4) Antipaltelet Trailists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:81-106, 1994

書評

書評を投稿する

最近チェックした商品履歴

Loading...